Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

EBioMedicine

Volumn 6, Issue , 2016, Pages 50-58

  Holmgaard, Rikke B ^a   Zamarin, Dmitriy ^a,b,c   Lesokhin, Alexander ^a,b,c   Merghoub, Taha ^a   Wolchok, Jedd D ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Weill Cornell Medical Center   (United States)

Author keywords

CSF 1R; CTLA 4; IDO; Immunotherapy; MDSCs; PD 1

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENZYME INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL STRUCTURE; COLON TUMOR; CYTOKINE PRODUCTION; FLOW CYTOMETRY; IMMUNITY; MOUSE; MURINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; HUMAN; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELL; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975743991     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.024     Document Type: Article

References (50)

1. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schafer R., Stanley E.R., Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004, 64:5378-5384.
2. Caescu C.I., Guo X., Tesfa L., Bhagat T.D., Verma A., Zheng D., Stanley E.R. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21. Blood 2015, 125:e1-13.
3. Cavnar M.J., Zeng S., Kim T.S., Sorenson E.C., Ocuin L.M., Balachandran V.P., Seifert A.M., Greer J.B., Popow R., Crawley M.H., Cohen N.A., Green B.L., Rossi F., Besmer P., Antonescu C.R., DeMatteo R.P. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J. Exp. Med. 2013, 210:2873-2886.
4. Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., Segall J.E. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 2012, 18:519-527.
5. Curran M.A., Allison J.P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009, 69:7747-7755.
6. Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., Stanley E.R. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99:111-120.
7. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirstrom K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
8. Diatta A., Piver E., Collin C., Vaudin P., Pages J.C. Semliki Forest virus-derived virus-like particles: characterization of their production and transduction pathways. J. Gen. Virol. 2005, 86:3129-3136.
9. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
10. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F., Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010, 40:22-35.
11. Elmore M.R., Najafi A.R., Koike M.A., Dagher N.N., Spangenberg E.E., Rice R.A., Kitazawa M., Matusow B., Nguyen H., West B.L., Green K.N. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 2014, 82:380-397.
12. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
13. Gunturu K.S., Rossi G.R., Saif M.W. Immunotherapy updates in pancreatic cancer: are we there yet?. Ther.Adv.Med.Oncol. 2013, 5:81-89.
14. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
15. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., Shankar S., Chen T.C., Korman A., Allison J.P., Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4712-4717.
16. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
17. Holmgaard R.B., Zamarin D., Munn D.H., Wolchok J.D., Allison J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 2013, 210:1389-1402.
18. Holmgaard R.B., Zamarin D., Li Y., Gasmi B., Munn D.H., Allison J.P., Merghoub T., Wolchok J.D. Tumor-expressed IDO Recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 2015, 13:412-424.
19. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012, 72:3125-3130.
20. Kim T.S., Cavnar M.J., Cohen N.A., Sorenson E.C., Greer J.B., Seifert A.M., Crawley M.H., Green B.L., Popow R., Pillarsetty N., Veach D.R., Ku A.T., Rossi F., Besmer P., Antonescu C.R., Zeng S., Dematteo R.P. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin. Cancer Res. 2014, 20:2350-2362.
21. Kitano S., Postow M.A., Ziegler C.G., Kuk D., Panageas K.S., Cortez C., Rasalan T., Adamow M., Yuan J., Wong P., Altan-Bonnet G., Wolchok J.D., Lesokhin A.M. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. CancerImmunol.Res. 2014, 2:812-821.
22. Le D.T., Lutz E., Uram J.N., Sugar E.A., Onners B., Solt S., Zheng L., Diaz L.A., Donehower R.C., Jaffee E.M., Laheru D.A. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 2013, 36:382-389.
23. Li J., Chen K., Zhu L., Pollard J.W. Conditional deletion of the colony stimulating factor-1 receptor (c-fms proto-oncogene) in mice. Genesis 2006, 44:328-335.
24. Li X., Loberg R., Liao J., Ying C., Snyder L.A., Pienta K.J., McCauley L.K. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009, 69:1685-1692.
25. Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., Halenbeck R., Wu G., Zhou A., Behrens D., Hollenbaugh D., Linnemann T., Qin M., Wong J., Chu K., Doberstein S.K., Williams L.T. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008, 320:807-811.
26. Lutz E., Yeo C.J., Lillemoe K.D., Biedrzycki B., Kobrin B., Herman J., Sugar E., Piantadosi S., Cameron J.L., Solt S., Onners B., Tartakovsky I., Choi M., Sharma R., Illei P.B., Hruban R.H., Abrams R.A., Le D., Jaffee E., Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann. Surg. 2011, 253:328-335.
27. Manthey C.L., Johnson D.L., Illig C.R., Tuman R.W., Zhou Z., Baker J.F., Chaikin M.A., Donatelli R.R., Franks C.F., Zeng L., Crysler C., Chen Y., Yurkow E.J., Boczon L., Meegalla S.K., Wilson K.J., Wall M.J., Chen J., Ballentine S.K., Ott H., Baumann C., Lawrence D., Tomczuk B.E., Molloy C.J. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol. Cancer Ther. 2009, 8:3151-3161.
28. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., Hewitt S., Udupi G.M., Gallagher W.M., Wegner C., West B.L., Wang-Gillam A., Goedegebuure P., Linehan D.C., DeNardo D.G. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
29. Mok S., Koya R.C., Tsui C., Xu J., Robert L., Wu L., Graeber T.G., West B.L., Bollag G., Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74:153-161.
30. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117:1147-1154.
31. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., Heimann D.M., Klebanoff C.A., Yu Z., Hwang L.N., Feigenbaum L., Kruisbeek A.M., Rosenberg S.A., Restifo N.P. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 2003, 198:569-580.
32. Patel S., Player M.R. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr. Top. Med. Chem. 2009, 9:599-610.
33. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., Duray P.H., Steinberg S.M., Allison J.P., Davis T.A., Rosenberg S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8372-8377.
34. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., Johnson M., Lusis A.J., Cohen D.A., Iruela-Arispe M.L., Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
35. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., Olson O.C., Quick M.L., Huse J.T., Teijeiro V., Setty M., Leslie C.S., Oei Y., Pedraza A., Zhang J., Brennan C.W., Sutton J.C., Holland E.C., Daniel D., Joyce J.A. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
36. Ribas A., Comin-Anduix B., Economou J.S., Donahue T.R., de la Rocha P., Morris L.F., Jalil J., Dissette V.B., Shintaku I.P., Glaspy J.A., Gomez-Navarro J., Cochran A.J. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 2009, 15:390-399.
37. Richardsen E., Uglehus R.D., Johnsen S.H., Busund L.T. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res. 2015, 35:865-874.
38. Robert C., Thomas L., Bondarenko I., O'Day S., D.J M, Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
39. Royal R.E., Levy C., Turner K., Mathur A., Hughes M., Kammula U.S., Sherry R.M., Topalian S.L., Yang J.C., Lowy I., Rosenberg S.A. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33:828-833.
40. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
41. Sluijter M., van der Sluis T.C., van der Velden P.A., Versluis M., West B.L., van der Burg S.H., van Hall T. Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One 2014, 9.
42. Srivastava M.K., Zhu L., Harris-White M., Kar U.K., Huang M., Johnson M.F., Lee J.M., Elashoff D., Strieter R., Dubinett S., Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012, 7.
43. Strachan D.C., Ruffell B., Oei Y., Bissell M.J., Coussens L.M., Pryer N., Daniel D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013, 2.
44. Tarhini A.A., Butterfield L.H., Shuai Y., Gooding W.E., Kalinski P., Kirkwood J.M. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 2012, 35:702-710.
45. Wei S., Nandi S., Chitu V., Yeung Y.G., Yu W., Huang M., Williams L.T., Lin H., Stanley E.R. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J. Leukoc. Biol. 2010, 88:495-505.
46. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., Burke M.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman A.J., Wigginton J.M., Gupta A., Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
47. Xu J., Escamilla J., Mok S., David J., Priceman S., West B., Bollag G., McBride W., Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate Cancer. Cancer Res. 2013, 73:2782-2794.
48. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
49. Zhang C., Ibrahim P.N., Zhang J., Burton E.A., Habets G., Zhang Y., Powell B., West B.L., Matusow B., Tsang G., Shellooe R., Carias H., Nguyen H., Marimuthu A., Zhang K.Y., Oh A., Bremer R., Hurt C.R., Artis D.R., Wu G., Nespi M., Spevak W., Lin P., Nolop K., Hirth P., Tesch G.H., Bollag G. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5689-5694.
50. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., Wang-Gillam A., Goedegebuure S.P., Linehan D.C., DeNardo D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-5069.